Data from EMC - Curated by Toby Galbraith - Last updated 20 April 2017

Licensing authority

EMA (European Medicines Agency)


Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


Essential screening, diagnosis and best strategies to manage bedwetting

Visit Bedwetting

More information

Category Value
Agency product number EMEA/H/C/001085
Orphan designation No
Date First Approved 03-12-2009
Type Medicinal product subject to medical prescription
Marketing authorisation holder Glenmark Pharmaceuticals Europe Limited

Related Content